Multi-Cancer Early Detection: Understanding Galleri Cancer Screening & Liquid Biopsies

A liquid biopsy is a blood test that looks for signs of cancer without a tissue sample or imaging. Instead of sampling a tumor directly, it looks for cell free DNA (cfDNA), fragments of genetic material that all cells, including tumor cells, shed into the bloodstream as they die and get replaced.

Galleri cancer screenings, developed by GRAIL, are currently the most studied liquid biopsy built specifically for multi cancer early detection (MCED). It does not sequence the DNA itself. It looks at the methylation pattern on that cfDNA, a chemical signature that differs between healthy tissue and cancer tissue, and between cancer types. That methylation signature lets one blood draw screen for a signal shared across dozens of cancers and predict which organ or tissue it likely came from.

The process starts with a standard blood draw ordered through a physician. The sample is analyzed for cfDNA methylation patterns associated with cancer. There are two possible results:

• No Cancer Signal Detected. This is the result for most people tested. It does not rule out cancer, and it does not replace your regular screening schedule.
• Cancer Signal Detected. This result includes a predicted Cancer Signal Origin (CSO), meaning the test estimates which organ or tissue the signal most likely came from, to guide targeted follow-up testing like imaging or biopsy rather than a broad, undirected workup.

Galleri is explicitly designed to sit alongside guideline recommended screening, not to replace mammograms, colonoscopies, low dose CT for lung cancer, or any other established test. Every major study and the manufacturer’s own guidance are consistent on this point.

This is where “test, don’t guess” matters most, because the honest picture is more nuanced than “detects cancer early.” Accuracy depends heavily on cancer type and stage, and it is worth understanding both sides of that data before recommending or requesting this test.

Specificity is high.

Across major studies, Galleri specificity runs about 99.5 to 99.6 percent, which translates to a false-positive rate of roughly 1 in 250 people tested. This is the test’s clearest strength: it rarely tells a healthy person they may have cancer when they do not.

Sensitivity depends heavily on stage.

In case control studies, overall sensitivity across all cancer types and stages combined was 51.5 percent, and stage specific sensitivity ranged from about 17 percent in Stage I to about 90 percent in Stage IV. In plain terms, Galleri screening test is considerably better at flagging cancers that have already progressed than catching them at their earliest, most curable stage. This is the honest limitation, and any credible discussion of this technology needs to state it clearly.

Sensitivity is meaningfully higher for the deadliest cancers.

For a group of 12 cancers responsible for roughly two thirds of US cancer deaths, including lung, pancreatic, and liver cancer, all of which lack recommended screening today, sensitivity in interventional trial data has run in the 70 to 76 percent range. Because these are the cancers most likely to be found late and treated with the least success, this is where Galleri’s real world value case is strongest.

Positive predictive value has improved with newer data.

Early results from the original PATHFINDER study showed a PPV of about 43 percent. GRAIL’s larger, more recent PATHFINDER 2 interventional study reported a PPV around 60 to 62 percent, meaning roughly 6 in 10 people with a Cancer Signal Detected result were ultimately diagnosed with cancer.

Cancer Signal Origin prediction is reasonably accurate.

Across studies, the predicted tissue of origin has matched the confirmed cancer location in roughly 88 to 93 percent of cases, which is what allows a positive result to guide a targeted follow up rather than an open ended search.

Galleri is not currently FDA approved. It is offered as a laboratory developed test under CLIA regulation, available by physician order. GRAIL submitted a Premarket Approval application to the FDA in January 2026; the FDA’s Molecular and Clinical Genetics Panel is scheduled to review that application on September 23, 2026, and a formal approval decision would follow separately after that review. The test previously received FDA Breakthrough Device designation in 2018, which expedites review but is not approval itself.

This distinction matters. A laboratory developed test can be clinically useful and still be pre-approval. Patients and clinicians should understand which stage of regulatory review a test is in before assuming it carries the same standing as an FDA approved screening test like mammography.

At CorAeon, our clinical model is built around testing: metabolism, cardiovascular health, hormones, nutrients, and inflammation form the biomarker foundation of every longevity medicine plan. Multi cancer early detection testing is a separate, complementary layer on top of that foundation, not a replacement for it and not a replacement for guideline recommended cancer screening.

For the right patient, typically someone 50 and older, or younger with elevated personal or family risk, adding an MCED test to an already comprehensive screening plan can surface a category of cancer risk that standard workups are not built to catch. It is one more data point used to guide, not replace, clinical judgment.

Does a “No Signal Detected” result mean I don’t have cancer?

No. It lowers the likelihood but does not rule out cancer, particularly early stage cancer, where sensitivity is lowest. Regular guideline recommended screening should continue regardless of the result.

Is Galleri covered by insurance?

Coverage varies by insurer, and the test is not FDA approved, which affects how it is billed. Confirm current coverage and cash pay pricing directly with your provider before testing.

Who is a good candidate for Galleri cancer screening?

It is generally intended for adults 50 and older with an elevated risk of cancer, used alongside, not instead of, standard screening. Discuss your personal and family history with your physician to determine fit.

What happens if I get a Cancer Signal Detected result?

Your physician will order targeted diagnostic testing, typically imaging or biopsy, guided by the predicted Cancer Signal Origin, to confirm or rule out a diagnosis. A positive Galleri result is not itself a cancer diagnosis.

CorAeon Longevity & Functional Medicine builds every care plan on the principle of test, don’t guess, layering advanced biomarker panels and emerging technologies like multi cancer early detection testing onto guideline recommended care, never in place of it.